Pelthos Therapeutics Inc.
Datakwaliteit: 100%
PTHS
NYSE
Manufacturing
Chemicals
€ 22,50
▼
€ 0,40
(-1,75%)
Marktkapitalisatie: 75,50 M
Prijs
€ 22,50
Marktkapitalisatie
75,50 M
Dagbereik
€ 22,50 — € 22,99
52-Weeksbereik
€ 9,00 — € 54,29
Volume
3.086
Openen € 22,99
50D / 200D Gem.
€ 23,03
2,28% below
50D / 200D Gem.
€ 25,04
10,14% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -22,69 M
Capital efficient — spends only 0,59% of revenue on capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-167,39%
Onder sectorgemiddelde (-51,02%)
ROIC-53,84%
Net Margin-257,93%
Op. Margin-193,09%
Veiligheid
Debt / Equity
N/A
Current Ratio2,01
Interest Coverage-10,77
Waardering
PE (TTM)
-1,74
Boven sectorgemiddelde (-1,98)
P/B Ratio1,30
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (44 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,7 | -2,0 |
| P/B | 1,3 | 5,1 |
| ROE % | -167,4 | -51,0 |
| Net Margin % | -257,9 | -150,2 |
| Rev Growth 5Y % | — | 9,3 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 16,80 M | Net Income (TTM) | -43,32 M |
| ROE | -167,39% | ROA | -68,08% |
| Gross Margin | N/A | Operating Margin | -193,09% |
| Net Margin | -257,93% | Free Cash Flow (TTM) | -22,69 M |
| ROIC | -53,84% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,01 |
| Interest Coverage | -10,77 | Asset Turnover | 0,26 |
| Working Capital | 24,99 M | Tangible Book Value | -4,89 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,74 | Forward P/E | N/A |
| P/B Ratio | 1,30 | P/S Ratio | 4,50 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -30,05% | ||
| Market Cap | 75,50 M | Enterprise Value | 61,30 M |
| Per Share | |||
| EPS (Diluted TTM) | -23,04 | Revenue / Share | 5,01 |
| FCF / Share | -6,76 | OCF / Share | -6,73 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 0,59% | FCF Conversion | 52,38% |
| SBC-Adj. FCF | -26,64 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 16,80 M | — | — |
| Net Income | -43,32 M | -7,96 M | -7,38 M |
| EPS (Diluted) | -23,04 | -1,43 | — |
| Gross Profit | — | — | — |
| Operating Income | -32,43 M | -7,57 M | -6,86 M |
| EBITDA | — | — | — |
| R&D Expenses | 1,23 M | 1,18 M | 2,58 M |
| SG&A Expenses | 42,45 M | — | — |
| D&A | — | — | — |
| Interest Expense | 3,01 M | 581.055,0 | 14.370,0 |
| Income Tax | -7,39 M | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total Assets | 130,40 M | 1,37 M | 96.391,0 |
| Total Liabilities | 91,52 M | 4,08 M | 6,54 M |
| Shareholders' Equity | 38,88 M | -2,71 M | -6,44 M |
| Total Debt | — | — | — |
| Cash & Equivalents | 17,97 M | — | 100.000,0 |
| Current Assets | 53,41 M | 1,37 M | 96.391,0 |
| Current Liabilities | 25,99 M | 4,08 M | 6,54 M |
{"event":"ticker_viewed","properties":{"ticker":"PTHS","listing_kind":"stock","pathname":"/stocks/pths","exchange":"NYSE","country":"US"}}